Abstract
Approximately 15–25% of men who undergo radical prostatectomy for localized prostate cancer will experience a PSA-defined biochemical recurrence (BCR) of their cancer—men with poorly differentiated cancer, non-organ-confined disease, and positive surgical margins are at the highest risk. Accumulating evidence indicates that postoperative radiation therapy to the prostate bed favorably influences the course of disease in men with pathological features of poor prognosis. Three phase III randomized trials of adjuvant radiotherapy versus observation have reported improved freedom from BCR, and one study has reported improved metastasis-free survival and overall survival. Similar evidence from randomized trials for salvage radiotherapy is lacking; however, several observational studies have reported durable responses to salvage radiotherapy and reduced cancer-specific mortality in a substantial proportion of high-risk patients, provided that it is administered at the earliest evidence of BCR. The appeal of salvage radiotherapy is that a substantial proportion of patients with non-organ-confined cancer or positive surgical margins are cured after radical prostatectomy alone, thereby limiting the adverse effects of postoperative radiotherapy—which include urinary and bowel dysfunction, sexual dysfunction and secondary pelvic malignancies—to only those whose cancer was not cured by surgery. In the absence of data from randomized trials demonstrating the superiority of adjuvant radiotherapy over a surveillance strategy (with planned salvage radiotherapy at the earliest evidence of BCR), we advocate shared decision making between physicians and patients, based on the relative advantages and disadvantages of each approach.
Key Points
-
The predominant pattern of treatment failure in men with a rising PSA level after radical prostatectomy is locoregional
-
Postoperative radiotherapy (as adjuvant or salvage therapy) can reduce the risk of PSA progression and distant metastasis and improve overall and cancer-specific survival
-
Adjuvant radiotherapy for men with positive surgical margins, extraprostatic extension, or seminal vesicle invasion is supported by evidence from three large randomized trials
-
Salvage radiotherapy can have similar outcomes to immediate adjuvant radiotherapy if it is administered at the earliest evidence of biochemical recurrence
-
We advocate shared decision making with patients based on the advantages and disadvantages of adjuvant radiotherapy over a surveillance strategy, with planned salvage radiotherapy at the earliest evidence of recurrence
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Burkhardt, J. H. et al. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J. Clin. Oncol. 20, 2869–2875 (2002).
Stephenson, A. J. et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Natl Cancer Inst. 98, 715–717 (2006).
Vickers, A. J. et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J. Natl Cancer Inst. 99, 1171–1177 (2007).
Moul, J. W. Prostate specific antigen only progression of prostate cancer. J. Urol. 163, 1632–1642 (2000).
Kupelian, P. A. et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J. Clin. Oncol. 20, 3376–3385 (2002).
Pound, C. R., Partin, A. W., Epstein, J. I. & Walsh, P. C. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol. Clin. North Am. 24, 395–406 (1997).
Patel, A., Dorey, F., Franklin, J. & deKernion, J. B. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J. Urol. 158, 1441–1445 (1997).
Roberts, S. G. et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin. Proc. 76, 576–581 (2001).
Ornstein, D. K. et al. Evaluation and management of men whose radical prostatectomies failed: results of an international survey. Urology 52, 1047–1054 (1998).
Bill-Axelson, A. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 352, 1977–1984 (2005).
Lightner, D. J., Lange, P. H., Reddy, P. K. & Moore, L. Prostate specific antigen and local recurrence after radical prostatectomy. J. Urol. 144, 921–926 (1990).
Leventis, A. K., Shariat, S. F. & Slawin, K. M. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 219, 432–439 (2001).
Raj, G. V., Partin, A. W. & Polascik, T. J. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 94, 987–996 (2002).
Sella, T. et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231, 379–385 (2004).
Stephenson, A. J. et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291, 1325–1332 (2004).
Stephenson, A. J. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J. Clin. Oncol. 25, 2035–2041 (2007).
Stephenson, A. J. & Slawin, K. M. The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy. Nat. Clin. Pract. Urol. 1, 90–96 (2004).
Katz, M. S. et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J. Clin. Oncol. 21, 483–489 (2003).
Swanson, G. P. et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J. Clin. Oncol. 25, 2225–2229 (2007).
Thompson, I. M. et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol. 181, 956–962 (2009).
Bolla, M. et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366, 572–578 (2005).
Wiegel, T. et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96–02/AUO AP 09/95. J. Clin. Oncol. 27, 2924–2930 (2009).
MacDonald, O. K. et al. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ? Urology 64, 760–764 (2004).
Trock, B. J. et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299, 2760–2769 (2008).
Messing, E. M. et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 341, 1781–1788 (1999).
Messing, E. M. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 7, 472–479 (2006).
Eggener, S. E. et al. Predicting prostate cancer-specific mortality after radical prostatectomy based on the pathological features of prostate cancer. J. Urol. 185, 869–875 (2011).
Schroder, F. H. et al. Early versus delayed endocrine treatment of pN1–3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846—a phase III study. J. Urol. 172, 923–927 (2004).
Schroder, F. H. et al. Early versus delayed endocrine treatment of T2-T3 pN1–3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur. Urol. 55, 14–22 (2009).
Bolla, M. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360, 103–106 (2002).
Shipley, W. U. et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 281, 1598–1604 (1999).
Hanks, G. E. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J. Clin. Oncol. 21, 3972–3978 (2003).
Bolla, M. et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360, 2516–2527 (2009).
Da Pozzo, L. F. et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur. Urol. 55, 1003–1011 (2009).
Potosky, A. L. et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J. Natl Cancer Inst. 94, 430–437 (2002).
Smith, M. R. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 97 (Suppl. 3), 789–795 (2003).
D'Amico, A. V. et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol. 25, 2420–2425 (2007).
Berry, D. A. et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 353, 1784–1792 (2005).
Krook, J. E. et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 324, 709–715 (1991).
Pound, C. R. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281, 1591–1597 (1999).
Anscher, M. S. Salvage radiotherapy for recurrent prostate cancer: the earlier the better. JAMA 291, 1380–1382 (2004).
Anscher, M. S. Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen. Int. J. Cancer 96, 91–93 (2001).
Trabulsi, E. J. et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3–4N0 prostate cancer. Urology 72, 1298–1304 (2008).
Taylor, N. et al. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 56, 755–763 (2003).
Valicenti, R. K. et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int. J. Radiat. Oncol. Biol. Phys. 45, 53–58 (1999).
Anscher, M. S., Robertson, C. N. & Prosnitz, R. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. Int. J. Radiat. Oncol. Biol. Phys. 33, 37–43 (1995).
Catton, C. et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother. Oncol. 59, 51–60 (2001).
Stephenson, A. J. et al. Location, extent, and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy compared to their presence or absence. J. Urol. 182, 1357–1363 (2009).
Bianco, F. J. Jr, Scardino, P. T. & Eastham, J. A. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology 66 (Suppl. 5), 83–94 (2005).
Hull, G. W. et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J. Urol. 167 (2 Pt 1), 528–534 (2002).
Thompson, I. M. Jr et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296, 2329–2335 (2006).
Van Poppel, H. et al. Adjuvant radiotherapy after radical prostatectomy in patients with pathologically high risk prostate cancer: 10-Year follow-up results. Eur. Urol. Suppl. 10, 93 (Abstract 227) (2011).
Van Cangh, P. J. et al. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J. Urol. 159, 164–166 (1998).
Van der Kwast, T. H. et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J. Clin. Oncol. 25, 4178–4186 (2007).
Cox, J. D. et al. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J. Clin. Oncol. 17, 1155 (1999).
Stephenson, A. J. et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol. 23, 7005–7012 (2005).
Brenner, D. J., Curtis, R. E., Hall, E. J. & Ron, E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88, 398–406 (2000).
Moon, K., Stukenborg, G. J., Keim, J. & Theodorescu, D. Cancer incidence after localized therapy for prostate cancer. Cancer 107, 991–998 (2006).
Acknowledgements
C. P. Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the Medscape, LLC-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Contributions
Both authors contributed equally to researching data for the manuscript, writing, and editing of this article before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Patel, A., Stephenson, A. Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage?. Nat Rev Urol 8, 385–392 (2011). https://doi.org/10.1038/nrurol.2011.80
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2011.80
This article is cited by
-
Changes in prostate-specific antigen midway through salvage radiotherapy may be associated with long-term outcomes
Journal of Radiation Oncology (2019)
-
Roles of Distal and Genic Methylation in the Development of Prostate Tumorigenesis Revealed by Genome-wide DNA Methylation Analysis
Scientific Reports (2016)
-
Utilization of PSA measurement at three months following salvage radiation therapy to predict future biochemical outcome
Journal of Radiation Oncology (2014)
-
Lack of association between COX-2 staining level and biochemical recurrence following salvage radiation therapy for recurrent prostate cancer
Journal of Radiation Oncology (2013)
-
Organbegrenztes Prostatakarzinom mit positivem Resektionsrand
Der Urologe (2012)